infection is not a contraindication to thrombolysis, there has been limited detailed reporting on the practical use and outcomes of thrombolysis for AIS in this population. 4 Registries, such as Get With The Guidelines, or large cohorts, such as the Framingham Heart Study, do not systematically test HIV. 5 We retrospectively identified HIV-infected patients who received intravenous tPA (tissue-type plasminogen activator) for presumed AIS in 7 large inner-city US academic medical centers.
Materials and Methods

Ethics Approvals
Case files were reviewed with the approval of the institutional review boards at each participating center with individual informed consent waived. We adhered to the Transparency and Openness Promotion Guidelines; however, data cannot be shared because of the small numbers of HIV-infected cases.
Search
We searched the medical records of US teaching hospitals where we worked and had collaborations: 12 patients were found at the New York-Presbyterian/Columbia University Medical Center 
Data Extraction and Collection
Each patient's medical record was reviewed by at least one boardcertified neurologist for the accuracy of diagnoses and confirmed use of intravenous tPA. Prespecified variables were extracted from the records by neurologists on a standardized spreadsheet and deposited in a centralized database. Inclusion criteria were as follows: ≥16 years old, documented history of HIV, initial clinical diagnosis of AIS, 7 documented administration of intravenous tPA for AIS, and available data on outcomes at last follow-up in the medical record even if at the time of hospital discharge or if the last follow-up was death. All cases had to have HIV infection before the AIS or documented at the same admission. All AIS cases were confirmed by brain computed tomography or magnetic resonance imaging or both. We defined a stroke mimic as a case in whom stroke was clinically diagnosed, but on follow-up >24 hours later, there was no radiographic evidence for acute stroke, and an alternative clinical diagnosis was determined at discharge. 8 CD4 count and viral load closest to time of stroke were recorded. Acquired immunodeficiency syndrome was defined as <200 CD4 cells/mm 3 . 9 Additional laboratory investigations including cerebrospinal fluid and testing for CNS OIs, such as varicella zoster virus, Cryptococcus species, Mycobacterium tuberculosis, John Cunningham virus, and Treponema pallidum, were reviewed.
The outcomes included (1) stroke versus stroke mimic, (2) modified Rankin Scale score 10 at last follow-up, and (3) intracerebral hemorrhage postintravenous tPA.
Results
We identified 33 HIV-infected patients (24 men [73%], 11 black, 8 white, 4 Hispanic) treated with intravenous tPA for AIS, of whom 10 were stroke mimics (6 men, 60%; Table 1 ). The remaining 23 (18 men, 78%) had neuroimaging-confirmed AIS. The median age of the entire cohort at the time of stroke presentation was 52 years. Their CD4 counts nearest the time of stroke ranged from 4 to 1340 cells/mm 3 (median, 324). The viral loads were less than the limit of detection in 16 of 33 (48%) and ranged from 32 to 287 000 copies/mL (mean, 52 409; median, 2827) in the remaining 17 patients. Their mean National Institutes of Health Stroke Scale (NIHSS) score was 9 (median, 6; range, 2-24), and the mean time from symptom onset to the administration of intravenous tPA was 144 minutes (median, 159; range, 46-260).
Morbidity and Mortality
No patient died during the hospitalization. All were alive at last available follow-up, which was at a median of 90 days (mean, 79 days; range, 1-420 days). The median follow-up modified Rankin Scale score was 1 (mean, 1.7; range, 0-5) for the 33-patient cohort and 2 (mean, 2.3; range, 0-5) for the 23-patient actual stroke cohort.
Efficacy
Among the 23 patients with true ischemic stroke, discharge NIHSS score was available for 16. These 16 patients showed a decrement of their average NIHSS score from 9 at presentation to 4 at hospital discharge (mean, 9 days; median, 6 days; range, 2-29).
Hemorrhagic Transformation
Two patients (6%) experienced hemorrhagic transformation, both of which were nonfatal and both patients had true AIS. One had hemorrhagic transformation occupying <30% of the infarct size and the other had a hemorrhage size that could not be assessed (Appendix II in the online-only Data Supplement). The discharge NIHSS score and whether hemorrhagic transformation was symptomatic in these cases were unavailable.
Patients With Acquired Immunodeficiency Syndrome
Ten patients (30%) had acquired immunodeficiency syndrome at the time of stroke, 9 5 of whom were not taking antiretroviral therapy at the time of stroke onset. CNS OIs occurred in a higher proportion in this group (20% versus 4%) compared with those with CD4 counts >200 cells/mL. There were no observed differences in other clinical features or outcomes (Table 2) .
Concomitant Infections and Intravenous Drug Use
Cerebrospinal fluid was evaluated in 9 patients and demonstrated varicella zoster virus IgG in 2 (22%) cases and no source of infection in the others. One patient had a highly positive serum Venereal Disease Research Laboratory but no cerebrospinal fluid pleocytosis. These 3 patients (2 with varicella zoster virus CNS vasculitis and 1 with presumed meningovascular syphilis), 7 others who were actively using intravenous illicit drugs (3 cocaine, 1 heroin, and 3 unspecified), and an additional 3 with past intravenous drug use (1 heroin and 2 unspecified) all did not experience hemorrhagic transformation (Table I in the online-only Data Supplement).
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Discussion
Our report is relevant to the care of HIV patients presenting with presumed AIS who are eligible for intravenous tPA. We observed no fatalities. Hemorrhagic transformation of the ischemic stroke occurred in 6% of HIV-infected patients with presumed AIS. Although this percentage seems within the range observed in the general population, 11 our small sample size means this point estimate has a wide range of confidence (1%-20%). No patient with CNS OI or current or past illicit drug use experienced hemorrhagic transformation. We report the safe use of tPA in 10 HIV patients who did not have ischemic strokes. Although other studies have reported the safe administration of intravenous tPA to patients with stroke mimics, 12, 13 we extend this finding to the population with potential CNS OIs. Although efficacy data were not available for the entire cohort, there was a clinically significant reduction in NIHSS score post-thrombolysis (decrement from 9 to 4 on average).
We acknowledge several limitations. We depended on retrospective data collection at multiple large US academic medical centers that have differences in population characteristics, HIV prevalence, and likely physician decision-making patterns over time. In some cases, there were missing data on the variables of interest. The follow-up duration and search years could not be unified across sites because of different medical records systems, registries, and software searching programs. We were unable to obtain long-term follow-up on all patients but had a reasonable observation time for short-term outcomes with a median of 90 days. If patients were followed for longer, more uniform amounts of time, we would be better able to comment on outcomes, fatality, and safety. It is possible that other patients had HIV and were untested for it, undercounting the number of cases. Because HIV testing is not routine in patients with AIS, it is likely some cases were unrecognized or undisclosed and therefore uncoded and not included here. The impact of this undercounting is uncertain, that is, whether this increases or decreases the true hemorrhagic conversion rate. Data on whether the hemorrhagic transformation was symptomatic versus only radiographic was not available. In addition, by using International Classification of Diseases codes to identify most patients, we relied on the accuracy and completeness of the hospitals' billing records.
Our report improves on the overall lack of information on acute stroke treatment for HIV-infected adults. Given the small number of cases at any one center, we collectively gathered all available data on HIV-infected tPA use for AIS, including the range of HIV-infected patients from severely immunosuppressed to treated with highly active antiretroviral therapy. Overall, our data are reassuring that both stroke and stroke mimic HIV-infected patients received intravenous tPA without short-term fatalities, even in the setting of CNS OIs, high degrees of immunosuppression, and other comorbidities. We hope this work will lead to the eventual development of a shared patient registry and improved documentation of HIV infection in existing registries for future patients.
Sources of Funding
This study was supported by a Canadian Institute for Health Research fellowship grant to Dr Mateen and National Institutes of Health 5T32AI007387-27 to Dr Gutierrez. 
